Make the Switch

Make the Switch

Inducible and reversible gene silencing

Inducible and reversible gene silencing

Inducible and reversible gene silencing

Unmatched Pace

Unmatched Pace

We generate proprietary RNAi animal models for pre-clinical and drug discovery studies in as little as 3 months, offering a unique in vivo platform for mimicking drug treatment and validating new drug targets with high predictive power.

We generate proprietary RNAi animal models for pre-clinical and drug discovery studies in as little as 3 months, offering a unique in vivo platform for mimicking drug treatment and validating new drug targets with high predictive power.

Our sensor assay enables parallel functional evaluation of ~20,000 RNAi triggers, selecting the most potent ones.

We only use single-copy integration, avoiding miRNA saturation and reducing off-targeting.

Doxycycline induces gene knockdown. Withdrawal of doxycycline results in pre-knockdown levels of expression.

Advantages of RNAi Models

Advantages of RNAi Models

Inducible and reversible gene silencing

Mimic drug therapy and validate new drug targets in vivo.

Inducible and reversible gene silencing

Mimic drug therapy and validate new drug targets in vivo.

Fine tuned gene silencing

Control the extent of gene suppression in a dose-dependent manner

Fine tuned gene silencing

Control the extent of gene suppression in a dose-dependent manner

Fast and cost-effective

Our engineering strategies decreased the timelines of animal model generation from years to <6 months.

Multiple gene silencing

RNAi can be employed to simultaneously silence the expression of two or more genes

The Power of Reversibility

The Power of Reversibility

Mirimus has fused together unparalleled expertise of RNA interference technology and genetic engineering of mouse models to create advanced platforms for rapid and cost-effective production of customized RNAi mouse models with potent, reversible gene silencing.

Activation of the Wnt pathway, often through deregulation of APC, is one of the most frequent events in human cancers. To model this event in mice, we inducibly silenced Apc using RNAi. After 4-6 weeks of doxycycline treatment, all mice developed leukemia/lymphomas, which were transplanted to secondary recipients. Shown in the video is one animal that presented with lymphoma associated hind limb paralysis at 4 weeks post transplantation. After 3 days following doxycycline withdrawal, the mouse regained full mobility. Our shAPC RNAi mice enabled us for the first time to explore the role of APC suppression and its continued deregulation in tumor maintenance.